Why the Dimerix (ASX:DXB) share price is up today

The Dimerix Ltd (ASX: DXB) share price is rising ttoday after the company announced its involvement in a trial on COVID-19 therapies.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The Dimerix Ltd (ASX: DXB) share price is rising today after the biopharmaceutical company announced its involvement in a trial on COVID-19 therapies.

Dimerix will be involved in the trial, named CLARITY 2.0, which has received approval from the Central Independent Ethical Review Board in India. It is expected to begin in April.

At the time of writing, the Dimerix share price has risen by 4% to 25 cents.

Dimerix's involvement in the CLARITY 2.0 trial

Dimerix's lead drug candidate, DMX-200, will be included in the CLARITY 2.0 trial, which will study treatment options for COVID-19.

CLARITY 2.0 will be running in India, where it will combine doses of DMX-200 with blood pressure medication to treat the respiratory symptoms associated with COVID-19.

The trial will involve 600 patients infected with COVID-19, who will be treated for 28 days and supervised for 26 weeks.

CLARITY 2.0 will be led by the University of Sydney's Professor Meg Jardine from the NHMRC Clinical Trials Centre. It will be run in collaboration with the George Institute for Global Health India.

Professor Meg Jardine spoke to BiotechDispatch:

The SARS-CoV-2 virus downregulates and suppresses certain anti-inflammatory effects and that may tip the local lung environment towards inflammation and fibrosis and might be why the virus has such a devastating effect on lung tissue.

We generally see that people with chronic health conditions that include inflammatory drivers… are more vulnerable to respiratory complications if they contract the SARS-CoV-2 virus. Some of those inflammatory drivers interact with the blood pressure system which is why some common blood pressure medications may improve outcomes in COVID-19 disease.

Early results suggest that DMX-200 may have stronger anti-inflammatory effects when used in combination with these blood pressure medications.

It is the second clinical trial that involves using DMX-200 to treat the respiratory symptoms brought on by COVID-19.

About DMX-200

Dimerix's DMX-200 was originally intended to treat forms of kidney disease, with which it had positive results.

The drug is a CCR2-inhibitor, aimed at reducing the damage caused by inflammatory immune cells. Thus, the company highlights that DMX-200 may also support the long-term outcomes of COVID-19 patients.

Dimerix share price snapshot

At the time of writing, the Dimerix share price is up by 4% to 25 cents. It has a year to date return of 6% and is up 70% over the last 12 months.

Dimerix has a market capitalisation of approximately $48 million, with 198 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Three guys in shirts and ties give the thumbs down.
Share Fallers

Why Aurelia Metals, Centuria Office, Meeka Metals, and Resolute shares are tumbling today

These shares are having a tough time on Thursday. Let's find out why.

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why Clarity Pharmaceuticals, Kelsian, Life360, and Syrah shares are rising today

These shares are pushing higher on Thursday. But why?

Read more »

Woman checking out new TVs.
Broker Notes

Does JP Morgan think JB Hi-Fi shares can keep rising?

The retailer is up 16% for the year to date.

Read more »

Happy young woman saving money in a piggy bank.
Share Market News

These ASX shares could pay you passive income for life

Analysts think these income shares could be top picks for Aussie investors.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Share Market News

3 excellent ASX ETFs for beginners to buy in FY26

Let's see why these funds could be top picks for Aussie's starting their investment journey.

Read more »

A trio of ASX shares analysts huddle together in an office with computer screens all around them showing share price movements
Opinions

2 of the best ASX 200 shares to buy right now

I think these stocks are excellent buys for the long-term.

Read more »

A man in his 30s with a clipped beard sits at his laptop on a desk with one finger to the side of his face and his chin resting on his thumb as he looks concerned while staring at his computer screen.
Broker Notes

Should you buy CBA, Telstra, and Wesfarmers shares?

Let's see what analysts are saying about these blue chips.

Read more »

Concept image of a businessman riding a bull on an upwards arrow.
Opinions

I'm very bullish on these 2 ASX stocks

I think these are two of the best ASX investments money can buy.

Read more »